Meridian Biosci: (NASD: VIVO)
$22.01
0.31 (1.43%)
Volume 150,833
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 21.54 - 22.02 |
| 52wk Low - High | 16.19 - 23.05 |
| Previous Close | 21.70 |
| Avg. Volume | 202,067 |
| Industry | MED PRODUCTS |
| Market Cap | 911.57 M |
| Div - Yield | 0.76 - 3.45 |
| Beta | 0.84 |
| PE (Forward) | 24.69 |
| Current Year Est. | 0.89 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 24.69 |
| PEG Ratio | 1.54 |
| Current Year Est. | 0.89 |
| Current Quarter Estimate | 0.22 |
| Most Accurate Estimate | 0.22 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 0.86 |
| Expected Earnings Growth | 16.00% |
Company Description
Meridian is a fully integrated life sciences company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (09/2013) |
Next Year (09/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.22 | 0.23 | 0.89 | 1.02 |
| Number of Estimates | 5 | 5 | 7 | 4 |
| Low Estimate | 0.21 | 0.21 | 0.86 | 0.97 |
| High Estimate | 0.23 | 0.24 | 0.91 | NA |
| Year Ago EPS | 0.21 | 0.21 | 0.82 | 0.89 |
| EPS Growth | 3.81% | 7.62% | 8.71% | 13.86% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| MERIDIAN BIOSCI | VIVO | 22.01 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| CYTOSORBENTS CP | CTSO | 0.12 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| ALERE INC | ALR | 26.30 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Meridien Completes Beta Trials
Dec 14, 2012
FDA Clears Meridian Ilumigene GAS
Sep 20, 2012
Report for VIVO
May 14, 2013
Financials
| EPS TTM | 0.86 |
| Sales | 174 |
| Net Income | 36 |
| Price/Earnings | 25.59 |
| Price/Book | 6.57 |
| Price/Cash Flow | 22.36 |
| Price/Sales | 5.11 |
News
Shares of Meridian Bioscience Under Pressure, Down 1.5% - Financial News Network Online - Market Movers
May 16, 2013
Antares Pharma has the Highest Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS) - Financial News Network Online - News Corner
May 8, 2013
Meridian Bioscience reports higher Q2 net earnings, provides outlook for 2013 - Datamonitor
May 7, 2013
WEALTHMAKERS.COM Issues Bullish Research Reports on URBN, USATP, VIVO - M2
May 7, 2013
Friday 5/3 Insider Buying Report: HTCH, VIVO - Marketnewsvideo.Com
May 3, 2013
Meridian Bioscience In Retrospect: Shares Down 1.4% Since Downgraded One Week Ago (VIVO) - Financial News Network Online - News Corner
May 3, 2013
Meridian Bioscience Makes a Move: Up 2.5% - Financial News Network Online - Market Movers
May 2, 2013
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio - Benzinga
Apr 30, 2013
Broker Recommendations
| Current ABR | 2.90 |
| ABR (Last Week) | 2.90 |
| # of recs in ABR | 10 |
| Average Target Price | 20.43 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 6 out of 72 |
